DelveInsight has added a new research study on X-Linked Retinitis Pigmentosa Market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030
X-Linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa (XLRP) caused by mutations in the Retinitis Pigmentosa GTPase regulator (RPGR) gene is the most common form of recessive RP. The RPGR gene is located on the X-chromosome; this is why the disease affects men and women in a different way.
Download full PDF X-Linked Retinitis Pigmentosa Sample copy @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market
X-Linked Retinitis Pigmentosa Market: Regions Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
List of Companies involved in X-Linked Retinitis Pigmentosa Market Report–
- Biogen
- MeiraGTx Limited/Janssen Pharmaceuticals
- And many others
X-Linked Retinitis Pigmentosa Treatment
Female carriers may also be affected with a milder form of the disease with peripheral pigmentary changes in the retina. XLRP often results in total blindness, and there is no specific treatment for this condition.
X-Linked Retinitis Pigmentosa Market Report
Mutations in the RPGR gene can be associated with a rod-cone or cone-rod dystrophy phenotype. It is initially identified with difficulties in scotopic visual function, where there is a predominant loss of rod photoreceptors. Also, there is peripheral vision deteriorates, resulting in visual field narrowing on perimetry findings. In some cases, patients also present early cone involvement and correspondingly impaired central visual acuity during early stages of the disease.
X-Linked Retinitis Pigmentosa Market Insights
XLRP is the condition that begins with night blindness leading to permanent blindness. It is an inherited condition and there is no specific treatment for this.
Current X-Linked Retinitis Pigmentosa Major Treatment Options
- Vitamin A palmitate
- Docosohexanoic acid (DHA)
- Optic nerve stimulation
- Lutein and/or zeaxanthin
- Visual prosthetics (brainPort)
- Calcium-channel blockers (Amlodipine, Diltiazem etc.)
Read Detailed X-Linked Retinitis Pigmentosa Market Report
1. Key Insights
2. Executive Summary of X-Linked Retinitis Pigmentosa (XLRP)
3. Competitive Intelligence Analysis for X-Linked Retinitis Pigmentosa (XLRP)
4. X-Linked Retinitis Pigmentosa (XLRP): Market Overview at a Glance
5. X-Linked Retinitis Pigmentosa (XLRP): Disease Background and Overview
6. Patient Journey
7. X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of X-Linked Retinitis Pigmentosa (XLRP) Treatment
11. Marketed Products
12. Emerging Therapies
13. X-Linked Retinitis Pigmentosa (XLRP): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of X-Linked Retinitis Pigmentosa (XLRP)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
X-Linked Retinitis Pigmentosa Market Report Highlights
- In the coming years, X-Linked Retinitis Pigmentosa (XLRP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence X-Linked Retinitis Pigmentosa (XLRP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for X-Linked Retinitis Pigmentosa (XLRP). Launch of emerging therapies will significantly impact the X-Linked Retinitis Pigmentosa (XLRP) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for X-Linked Retinitis Pigmentosa (XLRP)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
How Does This X-Linked Retinitis Pigmentosa Market Insights Help?
- The report will help in developing business strategies by understanding trends shaping and driving the X-Linked Retinitis Pigmentosa (XLRP) market
- To understand the future market competition in the X-Linked Retinitis Pigmentosa (XLRP) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for X-Linked Retinitis Pigmentosa (XLRP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for X-Linked Retinitis Pigmentosa (XLRP) market
- To understand the future market competition in the X-Linked Retinitis Pigmentosa (XLRP) market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/